JPRN-UMIN000034534已完成未知
Thalidomide for patients with severe autoimmune disease or autoinflammatory disease - Thalidomide for patients with severe autoimmune disease or autoinflammatory disease
Department of Pediatrics, Yokohama City University Hospital0 个研究点目标入组 5 人开始时间: 2018年10月17日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Pulmonary tuberculosis, active bacterial infection or deep mycotic infection 2. Infection of HIV, HCV or HBV 3. Administraion of live vaccine within 4 weeks 4. Pregnant subjects or subjects who do not agree with contraception during the study period 5. Others
研究者
相似试验
招募中
不适用
ow-dose thalidomide treatment for patients with relapsed and refractory multiple myeloma.multiple myelomaJPRN-UMIN000005960Gunma Hematological Disease Study Group70
进行中（未招募）
1 期
Efficacy and safety of thalidomide in pediatric patients with Crohn's diseaseCrohn's DiseaseEUCTR2016-000786-24-ITIRCCS Burlo Garofolo124
进行中（未招募）
1 期
Efficacy of thalidomide in the treatment of heavy and frequent nose bleeding in patients affected by hereditary hemorrhagic telangiectasiaSevere recurrent epistaxis in hereditary hemorrhagic telangiectasiaMedDRA version: 14.1Level: LLTClassification code 10038554Term: Rendu-Osler-Weber syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-004096-36-ITOSPEDALE POLICLINICO S. MATTEO31
尚未招募
不适用
Addition of oral thalidomide to standard antitubercular regimen for initial 2 months improves the outcome in patients of tubercular meningitis as compared to standard therapy alone.CTRI/2020/08/027438AIIMS Bhubaneswar
进行中（未招募）
1 期
Therapy of antibody-mediated autoimmune diseases by Bortezomib (TAVAB)Myasthenia Gravis Systemic Lupus ErythematosusRheumatoid ArthritisEUCTR2013-005362-19-DECharité - Universitätsmedizin Berlin18